Michel Vounatsos is Chief Executive Officer at Biogen and has served in this position and as a member of the Board of Directors since January 2017. Michel joined Biogen in 2016 as Executive Vice President, Chief Commercial Officer after a 20-year career at Merck. Prior to that, Michel held management positions at Ciba-Geigy.
During his first year as CEO, Biogen generated an all-time high of $12.3 billion in total revenues built on the company’s leadership position in multiple sclerosis, Spinal Muscular Atrophy (SMA) and biosimilars. Michel has also led Biogen to one of the most successful launches in biotech with SPINRAZA, the first and only approved treatment for SMA. SPINRAZA was also awarded the 2017 US Prix Galien prize.
With the goal of becoming the leader in neuroscience, Biogen doubled its historical productivity in 2017 by transitioning five pipeline candidates from research to development and added seven new clinical stage programs.
Michel is a strong supporter of diversity and inclusion, creating high performing and collaborative teams who are dedicated to making a difference in the lives of patients while maintaining the highest levels of ethics and transparency.
Michel is a member of the Board of PhRMA since 2017. He is also part of the Advisory Board at Tsinghua University, School of Pharmaceutical Sciences, in Beijing.
Michel received his C.S.C.T. certificate in Medicine from the Universite Victor Segalen, Bordeaux II, France, and his M.B.A. from the HEC School of Management in Paris.